Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab versus standard cetuximab-platinum-5FU as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma
MOH_2017-03-15_000184Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Bristol Myers Squibb. Started Jan 2017; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2017-03-15_000184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-15_000184.